Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fri, 19 April 2024 at 6:07 am GMT-4·5-min read
'I'm dying and raised £140,000 for a cancer vaccine. But now I have another tumour'
https://uk.news.yahoo.com/im-dying-raised-140-000-100728049.html
if your
Is this AF in the flesh?
a) 70+ doctors from 60+ hospitals endorse DCVax
as an improved GBM treatment vs SOC (you know this)
versus
5 ??? from 1 institution in Balogna Italy throwing shade
(but hang onto it - its all you got)
2 - There are those magic words - "PFS" data - as if to say -
if PFS data bad - and OS data outstanding - shitcan the results -
today - the whole planet understands - cancer/immuno trials
require OS data and hopefully 5 years worth
3 - I expect MHRA approval before July 1st - we can talk about
an apology then -
5 staff - 1 location - not exactly inspiring
1Department of Oncology, Azienda Unità Sanitaria Locale (AUSL) Bologna, 40139 Bologna, Italy; moc.liamg@38ottag.aidil (L.G.); ti.angolob.lsua@onnunid.oznecniv (V.D.N.)
2Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy; ti.bnsi@inosot.a (A.T.); ti.bnsi@inilotrab.ainafets (S.B.); ti.angolob.lsua@ireinar.aicul (L.R.)
etc
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296384/
Lidia Gatto,1
Vincenzo Di Nunno,1
Alicia Tosoni,2
Stefania Bartolini,2
Lucia Ranieri,2
Enrico Franceschi2,*
No
the point being - they (us and them) just talked (05 March 2024) - ~ 40 days ago
which further means -- they'll be talking soon - for the last time
NICE doesn't talk to grapefruit juice therapies or grapefruit juice farmers
only viable therapies for disease
Will AF apologize to dead GBM patients the day MHRA DCVax-L approves?
just asking .......
05 March 2024
A meeting was held between NICE and the company in early-February regarding next steps for the appraisal of DCVax-L for treating glioblastoma, and more information will be available in due course. NICE will continue liaising with the company and monitoring timelines.
https://www.nice.org.uk/guidance/indevelopment/gid-ta10143
=================================================
August 2023
Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities
George - just gotta uncork this
Poly-ICLC links at the bottom and I jiggled this all around to
suit my needs
Whats the point?
Poly-ICLC and DCVax-Direct is a dream come true
Remember - NWBO (poly off-label) just has to prove SAFETY not efficacy.
(so we don't have to wait for trial completions)
george
based on this and my own dumb ass 2 cents
https://www.cancer.gov/research/participate/clinical-trials/intervention/poly-iclc
do a search on dendritic cells
[color=red]
abc some questions about dcvax + poly-iclc + mhra
Assume DCVax approved tomorrow for GBM -
(1) could UK doctors ADD poly-iclc in an off-label basis?
NVCR
2022 - European Cancer - (DCVax-Direct targets)
https://ecis.jrc.ec.europa.eu/pdf/CancerEstimates2022_factsheet.pdf
Capacity
21 Dec, 2021, 09:24 ET
The Company anticipates that Phase 1A alone will be able to manufacture DCVax-L products for 45-50 patients per month, or 450-500 patients per year – a significant increase from the current manufacturing capacity of four to six patients per month which, to date, has been taking place in a GMP clean room facility in London, UK.
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-mhra-approval-of-license-for-gmp-manufacturing-at-sawston-uk-facility-301449083.html
Capacity
The initial production capacity comprises two manufacturing suites, occupying approximately 4,400 square feet on the ground floor. These two suites, together with substantial support space for process development, Quality Control testing, quarantined storage, cryostorage and other functions are anticipated to have potential capacity to produce dendritic cell vaccines for up to 40 to 45 patients per month, or approximately 450 to 500 patients annually. The buildout of Phase 1A of the Sawston facility was previously completed,
and the buildout of Phase 1B has been under way in 2022 and Q1 of 2023. Our buildout of the Sawston facility is designed to proceed in phases, as modules, both for efficiency in the timing of capital costs and to allow flexibility in operations and usage.
https://www.sec.gov/Archives/edgar/data/1072379/000141057823000185/nwbo-20221231x10k.htm
Source K: Brain tumour statistics
Current Key statistics for the UK
At least 88,000 children and adults are estimated to be living with a brain
tumour in the UK currently (England 68,500; Scotland 10,000; Northern
Ireland 5,500; Wales 4,000). 86% of the 88,000 are living with low grade
tumours and 14% with high grade tumours.5
Over 12,000 (actual 12,288) people in the UK are diagnosed with a
primary brain tumour every year1
https://assets.thebraintumourcharity.org/live/uploads/2023/06/Source-K_-Brain-Tumour-Statistics-June-2023-Final-Version.pdf
18,990
AMERICANS
will die from a malignant brain tumor in 2023
https://braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-facts/
Discussing NEW Cancer Treatment & Their Lawsuit Against Ken Griffin : NWBO & DCVax-L Cancer Vaccine
Tim alive due to dcvax
Prof. Dr. med. Frank Gansauge - Head Physician of the Department of Oncology, Immunotherapy and Dendritic Cell Therapy, conducts online consultations about the possibility of Dendritic Cell and Immunotherapy for cancer treatment
Order a consultation - 500 Euro - reg price 1500 Euro
2023 Sep 12
G
a) My figures are for the world
b) Agreed, they (my figures) are low because China - alone - has 47,000 *new*
cases of GBM a year. (Ain't gonna look for the link)
Chiugray
Your post was brilliant. Thank you for posting your insights.
Because GBM *kills* in *no time at all* - the take-up in DCVax-L
will be in a blink of the eye - except for the slow docs - who will be
eviserated and sued within 24 months.
My price discovery - just on GBM - is different - thats why I am posting
Prevalence of AMD
Phase 3 starts second half of 2024
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
Captain
Sorry to read about your wife.
I expect DCVax-L approval well before 150 days
so my vantage point is "certainty: and no "monsters in the closet" -
because there are none.
When I read flipper's "Russian" post I got excited because the
first thing I thought of was AF. It refuted him from a totally "out of left field"
point of view.
I am not trying to distract and I think the Michigan finding is interesting.
I will stop posting until approval.
KILLER COMPOUND PINPOINTS BRAIN CANCER BUT AVOIDS NORMAL CELLS
Note
“This is a just first step,” he adds. “Developing a treatment for human glioblastoma patients will take years of research. We hope to have human trials within five years.”
Sorry - I missed it.
protein called prosaposin
Cancers develop mechanisms to evade detection and subsequent killing by the immune system. One such strategy involves suppressing the presentation of tumor-associated antigens
is key for triggering immunity against tumors. Immune sentinels called dendritic cells (DCs) engulf dead cancer cells and use prosaposin to process tumor-derived antigens for subsequent display and activation of protective T lymphocytes.
Tumor growth results in the addition of complex sugar chains to prosaposin molecules in DCs, leading to prosaposin secretion and the depletion of lysosomal saposins.
Targeting tumor DCs with an engineered form of prosaposin enhances the antitumor immune response and improves tumor control. —Priscilla N. Kelly
https://www.science.org/doi/10.1126/science.adg1955
I know and thought others might be interested
Artemii Rynda
Dmitrii M. Rostovthev
Yulia M Zabrodskaya
Victor E. Olyushin
Abstract and Figures
Captain
Glioblastoma studies show promise
By University Communications, Friday, January 26th, 2024
(DCVax-L trial is mentioned)
Personalized immune therapy
MATTHEW COLLINS | BEING DIAGNOSED WITH CANCER WAS DEVASTATING, BUT THE VACCINE GAVE ME HOPE
2 HOURS AGO
(this is about DCVax-L)